CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance

Molecular Carcinogenesis

Volumn 54, Issue 11, 2015, Pages 1451-1466

  Afonso, Julieta ^a,b   Santos, Lúcio L ^c,d   Miranda Gonçalves, Vera ^a,b   Morais, António ^c   Amaro, Teresina ^c   Longatto Filho, Adhemar ^a,b,e,f   Baltazar, Fátima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

CD147; Chemoresistance; Monocarboxylate transporters; Tumor microenvironment; Urothelial bladder cancer

Indexed keywords

CARBONATE DEHYDRATASE IX; CD147 ANTIGEN; CISPLATIN; HERMES ANTIGEN; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; SMALL INTERFERING RNA; BSG PROTEIN, HUMAN; COTRANSPORTER; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER CELL LINE; BLADDER CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CELL MEMBRANE; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UROTHELIAL BLADDER CARCINOMA; DISEASE COURSE; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; BIOMARKERS, TUMOR; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; PROGNOSIS; RNA, SMALL INTERFERING; SURVIVAL RATE; SYMPORTERS; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS;

EID: 84945189106     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22222     Document Type: Article

References (51)

1. Colombel M, Soloway M, Akaza H, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 2008; 7:618-626.
2. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med 2013; 11:13.
3. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-1883.
4. Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. Cancer Genomics Proteomics 2010; 7:157-169.
5. Toole BP, Slomiany MG. Hyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance. Drug Resist Updat 2008; 11:110-121.
6. Slomiany MG, Grass GD, Robertson AD, et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 2009; 69:1293-1301.
7. Halestrap AP. The SLC16 gene family-Structure, role and regulation in health and disease. Mol Aspects Med 2013; 34:337-349.
8. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect: Insights from the past decade. Pharmacol Ther 2013; 137:318-330.
9. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: Why do cancers have high glycolysis? J Bioenerg Biomembr 2007; 39:251-257.
10. Brahimi-Horn MC, Bellot G, Pouyssegur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 2011; 21:67-72.
11. Xue YJ, Lu Q, Sun ZX. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol 2011; 28:1363-1372.
12. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13:4407-4414.
13. Afonso J, Longatto-Filho A, Baltazar F, et al. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. Eur J Surg Oncol 2011; 37:811-817.
14. Omran OM, Ata HS. CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer. Ultrastruct Pathol 2012; 36:145-152.
15. Klatte T, Seligson DB, Rao JY, et al. Carbonic anhydrase IX in bladder cancer: A diagnostic, prognostic, and therapeutic molecular marker. Cancer 2009; 115:1448-1458.
16. Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005; 11:2625-2636.
17. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: State of the art. J Bioenerg Biomembr 2012; 44:127-139.
18. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z, Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target 2012; 20:561-573.
19. Supuran CT. Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. World J Clin Oncol 2012; 3:98-103.
20. Amin MB, Srigley JR, Grignon DJ, et al. Urinary bladder cancer protocols and checklists. Northfield: College of American Pathologists 2005.
21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. New York: Springer Verlag; 2010.
22. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press 2004.
23. Pinto-Leite R, Carreira I, Melo J, et al. Genomic characterization of three urinary bladder cancer cell lines: Understanding genomic types of urinary bladder cancer. Tumour Biol 2014.
24. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2 and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010; 2010:427694.
25. Pinheiro C, Sousa B, Albergaria A, et al. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011; 26:1279-1286.
26. Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011; 11:312.
27. Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2013; 63:58-66.
28. Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR. Advances in platinum chemotherapeutics. Chemistry 2010; 16:7064-7077.
29. Schiavoni G, Gabriele L, Mattei F. The tumor microenvironment: A pitch for multiple players. Front Oncol 2013; 3:90.
30. Benton CR, Campbell SE, Tonouchi M, Hatta H, Bonen A. Monocarboxylate transporters in subsarcolemmal and intermyofibrillar mitochondria. Biochem Biophys Res Commun 2004; 323:249-253.
31. Miranda-Goncalves V, Honavar M, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets. Neuro Oncol 2013; 15:172-188.
32. Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: The ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J Biol Chem 2005; 280:27213-27221.
33. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000; 19:3896-3904.
34. Pinheiro C, Longatto-Filho A, Simoes K, et al. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 2009; 45:2418-2424.
35. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007; 67:4182-4189.
36. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 2003; 278:25285-25288.
37. Marieb EA, Zoltan-Jones A, Li R, et al. Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 2004; 64:1229-1232.
38. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4:528-539.
39. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4:33-45.
40. Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 2011; 117:1197-1209.
41. Rudrabhatla SR, Mahaffey CL, Mummert ME. Tumor microenvironment modulates hyaluronan expression: The lactate effect. J Invest Dermatol 2006; 126:1378-1387.
42. Toole BP. Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res 2009; 15:7462-7468.
43. Ohashi R, Takahashi F, Cui R, et al. Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell. Cancer Lett 2007; 252:225-234.
44. Torre C, Wang SJ, Xia W, Bourguignon LY. Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling. Arch Otolaryngol Head Neck Surg 2010; 136:493-501.
45. Wang SJ, Bourguignon LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006; 132:771-778.
46. Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012; 287:32800-32824.
47. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26:299-310.
48. Hussain SA, Palmer DH, Ganesan R, et al. Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 2004; 11:1005-1010.
49. Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, et al. Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomed Pharmacother 2013; 67:116-121.
50. Wang B, Xu YF, He BS, et al. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res 2010; 29:61.
51. Zhu C, Pan Y, He B, et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells. Oncol Rep 2011; 25:425-432.